ReviewMicroorganisms2022
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- Integrin ß4 is a receptor for emerging fungal pathogens from the genera Lomentospora and Scedosporium.PLoS pathogens · 2026Article
- MultisystemASM case reports · 2026Article
- DisseminatedBMJ case reports · 2026Article
- Structural barriers to antifungal drug development.Frontiers in cellular and infection microbiology · 2026Review
- From the Ground to the Clinic: The Evolution and Adaptation of Fungi.Journal of fungi (Basel, Switzerland) · 2025Review
- Case Commentary: Successful use of olorofim for the treatment of multi-drug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Successful use of olorofim for the treatment ofAntimicrobial agents and chemotherapy · 2025Article
- Computational design of an mRNA vaccine targeting antifungal-resistant Lomentospora prolificans.Scientific reports · 2025Article
- Masquerading Yeast: A Case Report ofOpen forum infectious diseases · 2025Article
- Successful management ofMedical mycology case reports · 2025Article
- Clinical significance and antifungal susceptibility profile of 103 clinical isolates ofJournal of clinical microbiology · 2025Article
- Clinical Significance and Therapeutic Challenges ofJournal of fungi (Basel, Switzerland) · 2025Article
- Clinical aspects and recent advances in fungal diseases impacting human health.The Journal of antimicrobial chemotherapy · 2025Review
- Evolving spectrum of Pneumocystis host specificity, genetic diversity, and evolution.FEMS microbiology reviews · 2025Review
- Successful Treatment of Lomentospora Prolificans Infection Following Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review.Infection and drug resistance · 2025Article
- Exploring the structural basis and functional immunodynamics of immunoglobulin M in host defense against fungal pathogens.Frontiers in immunology · 2025Review
- Emerging Fungal Infections of the Central Nervous System in the Past Decade: A Literature Review.Infectious disease reports · 2024Review
- The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective.Open forum infectious diseases · 2024Review
- Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.Clinical microbiology reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.